The International Journal of Neuropsychopharmacology
September 9, 2026
Marta Di Forti, Isabelle Austin-Zimmerman, Edoardo Spinazzola et al.
Abstract Background Epidemiological data have consistently shown an association between heavy cannabis use and increased risk of psychotic disorders. Nevertheless, not all cannabis users develop the illness. Evidence from other substance of abuse such as Alcohol suggest how genetic differences in enzymes involved in its metabolism influence individual response to the drug. No studies to data...
Harm Reduction Journal
September 7, 2026
Konstantinos Farsalinos
Background: The contemporary landscape of psychoactive substance regulation is characterized by a striking policy paradox. On one hand there is the gradual liberalization and mainstreaming of the cannabis market (the "Green Wave"), propelled by principles such as human rights, harm reduction, criminal justice reform, social equity, and economic efficiency. This coincides with a...
Zenodo (CERN European Organization for Nuclear Research)
September 7, 2026
Christian Alexander Brown
preprint
This research essay/article argues that cannabis can reasonably be described as psychedelic in a phenomenological sense, even though it is not pharmacologically classified as a classic serotonergic psychedelic such as LSD or psilocybin. The central distinction is between pharmacology and phenomenology: THC acts primarily through the endocannabinoid system, especially CB1 receptor signaling, yet...
Nature Communications
September 3, 2026
Eun-Kyung Hwang, Deborah Daphne, Charlie J Maddox et al.
The lateral habenula (LHb) integrates cortical and basal forebrain (BF) input and is implicated in negative affective states, but its involvement in negative affect associated with cannabis withdrawal is unknown. Here, effects of withdrawal from the psychoactive cannabis constituent, Δ9-tetrahydrocannabinol (Δ9-THC), on fear conditioning (FC) and LHb function were measured in rats using calcium...
Clinical Therapeutics
September 2026
Jonathon K. Lisano, Luiza Rosa, Greg Giordano et al.
Emerging research indicates that the use of cannabis products, particularly those higher in cannabidiol (CBD), may be anxiolytic. Physical activity is another modality observed to have anxiolytic effects. Despite evidence of cannabis and physical activity being paired together, there is limited research on the possible synergistic effects of physical activity and cannabis use on reductions in...
Journal of Neurochemistry
September 2026
Igor F Rangel, Melissa Chaves, Iohanna Pagnoncelli et al.
Adolescent cannabis exposure has been associated with an increased risk of schizophrenia; however, how genetic vulnerability shapes the long-term consequences of adolescent cannabinoid exposure remains poorly understood. Δ9-Tetrahydrocannabinol (THC), the principal psychoactive constituent of cannabis and the predominant cannabinoid in the THC-rich cannabis extract used here, primarily...
Drug and Alcohol Dependence
September 1, 2026
S. Vanegas, J. Marusich, J. Maturano et al.
BACKGROUND AND PURPOSE Cannabinoids, including Δ9-tetrahydrocannabinol (THC) and synthetic CB1 agonists elicit acute psychotropic effects that undergo tolerance with repeated exposure. In contrast, the effects of prolonged cannabinol (CBN) use are unknown. This study examined (1) the effects of repeated CBN administration on classic cannabimimetic outcomes, (2) whether these effects undergo...
Psychopharmacology
September 1, 2026
Renée Martin-Willett, Samantha N. Melendez, Kent E. Hutchison et al.
RATIONALE An estimated two-thirds of medical cannabis users in the United States are motivated by chronic pain, but clinical guidance remains guarded as to whether the potential benefit of cannabinoids for pain outweighs potential risks, such as effects on cognition. OBJECTIVES In a study where participants experienced benefits of cannabinoids for pain and tension, we evaluated cannabis effects...
Perspectives on Science and Christian Faith
September 1, 2026
Yong Fang Zhu, Kyra White
With the legalization of cannabis and the proliferation of products containing its main psychoactive component, tetrahydrocannabinol (THC), the use of cannabis-associated psychoactive substances has moved from the margins to the mainstream and, in the case of recreational marijuana, involves products of increasing potency. This development raises several specific interdisciplinary questions,...
Current Neuropharmacology
August 31, 2026
Harrison J. Elder, Bryan W. Jenkins, C. Austin Zamarripa et al.
Introduction: This narrative review systematically examines the available empirical evidence for interactions between delta-9-tetrahydrocannabinol (Δ9-THC or THC) and C. sativa’s other phytochemical constituents hypothesized to underpin the popular yet controversial notion of ‘entourage effects’ experienced with botanical cannabis. Many relevant preclinical and clinical studies have been...